Company intelligence / Profile preview

Denkers

Seal Beach, California, United Statesdenkersbv.com ↗

Ownership: Private
Employees: ~650
Development stage: Commercial

Overview

PROVENGE (sipuleucel-T), an autologous cellular immunotherapy, was the first FDA-approved treatment of its kind for metastatic castration-resistant prostate cancer. In pivotal Phase 3 trials, PROVENGE demonstrated a statistically significant improvement in overall survival compared to control, extending median survival by approximately 4.1 months and reducing risk of death by about 22.5%. Nearly 40,000 men have received this treatment since approval.

Therapeutic areas: Oncology
Modalities: Cellular therapyAutologous cellular immunotherapyBiologic
Industry: Biotech

Beyond the preview

Go deeper on Denkers.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Denkers.

Explore the full profile